21
Fri, Jun
53 New Articles

Norton Rose Fulbright and Clifford Chance Advise on EUR 730 Million Facilities for Polpharma

Norton Rose Fulbright and Clifford Chance Advise on EUR 730 Million Facilities for Polpharma

Poland
Tools
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

Norton Rose Fulbright, working with Harneys Cyprus, has advised a syndicate of banks on a new multicurrency term loan and revolving credit facility amounting to EUR 730 million for Windstorm Trading & Investments and Zaklady Farmaceutyczne Polpharma. Clifford Chance advised the borrowers.

The lending syndicate included ING Bank NV (London), Caixabank Poland, Bank Pekao, the EBRD, BNP Paribas Bank Polska, ING Bank Slaski, PKO Bank Polski, mBank, Bank Handlowy w Warszawie, and Santander Bank Polska.

According to NRF, Polpharma is the leader in the Polish pharmaceutical market and one of the leading drug manufacturers in Central and Eastern Europe. The company was founded in 1935. "Currently, they are part of a strong international pharmaceutical group, offering modern drugs, substances, and innovative solutions for patients and business partners worldwide. Its factories produce 400 million drug packages annually," the firm reported.

Back in 2021, both Norton Rose and Clifford Chance advised on another, PLN 800 million, financing for Polpharma (as reported by CEE Legal Matters on July 8, 2021).

The NRF team included Warsaw-based Partner Grzegorz Dyczkowski, Counsel Marta Kawecka, and Senior Associate Igor Kondratowicz as well as London-based Partner James Dunnett.

The Clifford Chance team included Partner Andrzej Stosio, Counsel Tomasz Szymura, Senior Associate Anna Miernik, and Associates Natalia Karasiewicz and Aleksandra Bialyszewska.

Our Latest Issue